Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
NASDAQ:ASND
Price:
135.9 USD
-0.75%
Market Closed
Updated:
Apr 28, 2024
Section:
Relative Value
The Relative Value of one
ASND
stock under the Base Case scenario is
222.55
USD.
Compared to the current market price of 135.9 USD,
Ascendis Pharma A/S
is
Undervalued by 39%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ASND
Relative Value
Base Case
222.55
USD
Undervaluation 39%
Valuation Multiples
Multiples Across Competitors
ASND Competitors Multiples
Ascendis Pharma A/S Competitors
Ascendis Pharma A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Ascendis Pharma A/S
NASDAQ:ASND
|
7.8B USD | 27.4 | -15.2 | -17.6 | -16.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
144.5B USD | 5.1 | 21.5 | 16.1 | 24.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.4B USD | 10.4 | 28.3 | 22.6 | 23.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.6B USD | 7.4 | 24.4 | 16.1 | 17.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132B AUD | 6.1 | 34.9 | 21.2 | 26.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.5B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 6 | -8.7 | -9.2 | -7.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
30.3B USD | 3.1 | 26.1 | 14.2 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
36.6T KRW | 16.8 | 68.3 | 41.9 | 57.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
